PCSK9 antibody marketing application received notification
October 9, 2024
Source: drugdu
73
On September 29, 2024, two acceptance numbers for Junshi Biosciences's PCSK9 antibody marketing application were notified, indicating that they have not been approved (possibly due to voluntary withdrawal or pending approval).
In April 2023, Junshi Biosciences received 4 acceptance numbers for its PCSK9 antibody market application, of which 2 were notified this time, and the other 2 have not yet received results. Four acceptance numbers involve two specifications (pre filled syringes, pre filled automatic syringes) and two indications. This two notifications indicate that a certain specification or indication has not been approved.
The competition for PCSK9 targets is particularly fierce. In addition to antibodies from Amgen and Sanofi, PCSK9 antibodies from Sinovac Biotech and PCSK9 siRNA from Novartis have already been approved for marketing. Among them, Novartis' PCSK9 siRNA only needs to be administered once every six months. For this target, there are more differentiated products under development, including Merck's PCSK9 oral macrocyclic peptide and Lilly's PCSK9 in vivo gene editing.
Source: https://pharm.jgvogel.cn/c1447501.shtml
By editor
Copyright©2024 Ddu. All rights reserved.
Read more on
- Over 5.7 billion! China’s dual antibody ADC goes global+1 November 21, 2024
- Is Jingtai Technology once again breaking through the “first AI pharmaceutical stock” halo and shedding? November 21, 2024
- Yangqi Medical Chip completes tens of millions of yuan in Pre-A round financing November 21, 2024
- Endovascular stent approved through priority green channel November 21, 2024
- Well-known products of foreign companies such as AZ, Eli Lilly, and Sanofi were disqualified November 21, 2024
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
